Liquid Biopsy: How a Blood Test Can Spot Cancer's DNA

For decades, confirming cancer meant cutting into tissue. A surgeon or radiologist would remove a small piece of a suspicious mass, and a pathologist would examine it under a microscope. That tissue biopsy is still the backbone of cancer diagnosis today. But tumors leave another trail, one that doesn't require a needle anywhere near the tumor itself: fragments of their own DNA, floating in the blood.

A liquid biopsy is a blood test built to find that trail. Instead of sampling the tumor directly, it looks for molecular debris the tumor has already shed into circulation. It's a fundamentally different way of asking the same question a tissue biopsy asks, and in some situations it can answer things tissue alone cannot.

Where Tumor DNA in the Blood Actually Comes From

Everyone, healthy or not, has small fragments of DNA drifting freely in their bloodstream. This is called cell-free DNA, and it's released constantly as cells throughout the body die and break apart in the ordinary course of turnover. Tumors do the same thing, only their cells die messily and often, shedding their own genetic fragments into the blood alongside everyone else's.

The portion of that cell-free DNA that specifically comes from tumor cells is called circulating tumor DNA, or ctDNA. It's a minority of the DNA in any blood sample, sometimes a tiny minority, but it carries something ordinary cell-free DNA doesn't: the mutations that make the tumor's cells cancerous in the first place. Finding and reading those mutations is the basis of the entire liquid biopsy approach. A large study examining blood samples across many cancer types and stages confirmed that this tumor-derived DNA can be detected in a meaningful share of patients, though how much is present varies a great deal depending on the cancer's type, size, and location.

What the DNA Fragments Can Tell Doctors

Because ctDNA carries the tumor's own mutations, sequencing it can reveal the genetic makeup of a cancer without ever touching the tumor directly. That matters because a single tumor isn't always genetically uniform. Different regions of the same tumor, or different metastases scattered around the body, can carry different mutations. A tissue biopsy only samples the one spot it was taken from, like judging an entire orchard from a single piece of fruit. Blood, by contrast, can pick up signals shed from multiple tumor sites at once, offering a broader, if blurrier, snapshot of the cancer's genetics.

Watching a Cancer Change in Real Time

Because a blood draw is far less invasive than a repeat tissue biopsy, ctDNA can be tested again and again over the course of treatment. That repeatability is what makes it useful for tracking how a tumor is behaving, not just what it looked like on day one. An early study that tracked mutant DNA levels in patients over time showed that rising or falling ctDNA tracked with how the tumor itself was responding to treatment, sometimes more sensitively than imaging could.

That sensitivity has a particularly useful application: catching resistance before it becomes visible. Cancers treated with targeted drugs often develop new mutations that let them evade the treatment. Because ctDNA reflects the tumor's current genetic state, repeated testing can sometimes flag a resistance mutation emerging weeks or months before a scan would show the tumor growing again. This doesn't mean liquid biopsy always catches resistance early, or that it can replace scans, but the underlying logic, that blood can register molecular changes before they become anatomical ones, is well supported.

Finding What's Left Behind After Surgery

Surgery can remove a visible tumor completely and still leave behind a handful of cancer cells too small for any scan to detect. This leftover disease is called minimal residual disease, and for years there was no good way to know who had it and who didn't. ctDNA testing after surgery offers one answer: if tumor DNA is still detectable in the blood once the visible tumor is gone, it suggests cancer cells remain somewhere in the body.

This was studied closely in patients with stage II colon cancer, a group where doctors have long struggled to decide who actually needs chemotherapy after surgery, since most of these patients are already cured by the operation alone. Researchers led by Jeanne Tie found that patients whose blood still showed detectable ctDNA after surgery were far more likely to have their cancer return than those whose ctDNA had cleared. That finding turned a blood test into something close to a crystal ball for recurrence risk, at least in this specific setting, and it's one of the clearest demonstrations of how liquid biopsy can reshape a treatment decision that used to rely mostly on guesswork.

Screening for Cancer Before Any Symptoms Appear

The most ambitious use of this technology is also its least settled: screening apparently healthy people for cancer they don't yet know they have. So-called multi-cancer early detection tests attempt this by scanning a single blood sample for signals, often patterns of DNA methylation, a chemical marking on DNA that tends to look different in cancer cells, that could point to any of several cancer types at once, along with a rough sense of where in the body the cancer might be.

Early validation studies of these tests, including large-scale efforts testing multi-analyte blood signatures and methylation-based signatures, have shown that cancer-associated signals can sometimes be detected and even localized to the right organ. But detection rates vary enormously by cancer type and stage, and these tests are not yet validated as a replacement for established screening tools like mammography or colonoscopy in the general population. They remain investigational, which is a meaningfully different status than approved for routine use.

Other Signals Riding Along in the Blood

DNA fragments aren't the only cancer-related material that circulates. Whole cancer cells sometimes break off from a tumor and travel through the bloodstream as circulating tumor cells, and cells throughout the body, cancerous and otherwise, release tiny membrane-bound particles called extracellular vesicles, or exosomes, carrying molecular cargo like RNA and proteins. Both are active areas of interest in blood-based cancer detection, reflecting the broader idea that a tumor leaves many kinds of trace evidence behind, not just DNA.

What Liquid Biopsy Still Can't Do

For all its promise, liquid biopsy has real limits. A negative result doesn't rule out cancer, since not every tumor sheds enough ctDNA to be detected, particularly early or small ones. A positive result isn't a diagnosis by itself either; it needs confirmation through imaging or tissue sampling before any treatment decision follows. The balance a test strikes between catching true cases, its sensitivity, and avoiding false alarms, its specificity, is central to how useful it actually is, and that balance differs across cancer types and test designs.

Tissue biopsy still remains the standard for diagnosing most cancers. Liquid biopsy is best understood right now as a complementary tool, one that is already changing how some cancers are monitored and how treatment decisions get made after surgery, while its role in screening the general population is still being defined through ongoing research.